James Healy - Jul 2, 2021 Form 4 Insider Report for Karuna Therapeutics, Inc. (KRTX)

Role: Director
Signature: /s/ Nathalie Auber, Attorney-in-Fact
Stock symbol: KRTX
Transactions as of: Jul 2, 2021
Transactions value $: $74,923
Form type: 4
Date filed: 7/7/2021, 06:48 PM
Previous filing: Jun 23, 2021
Next filing: Jul 26, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KRTX	Common Stock	Purchase	$74.9K	+636		$117.80	636	Jul 2, 2021	By Sofinnova Synergy Master Fund, LP	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $117.555 to $117.85, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2	All shares held by Sofinnova Synergy Master Fund, LP (the "Fund"). Sofinnova Synergy Fund GP, LLC (the "GP"), the general partner of the Fund, may be deemed to have sole voting and dispositive power over these shares, and Dr. James I. Healy and Dr. Eric Delbridge, the managing members of the GP, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein.

Content

The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $117.555 to $117.85, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (1) to this Form 4.

All shares held by Sofinnova Synergy Master Fund, LP (the "Fund"). Sofinnova Synergy Fund GP, LLC (the "GP"), the general partner of the Fund, may be deemed to have sole voting and dispositive power over these shares, and Dr. James I. Healy and Dr. Eric Delbridge, the managing members of the GP, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein.